MENU
MEDX
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

MEDX stock forecast, quote, news & analysis

The investment seeks to provide long-term growth of capital... Show more

Category: #Health
MEDX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for MEDX with price predictions
Sep 25, 2026

MEDX's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for MEDX turned positive on September 25, 2026. Looking at past instances where MEDX's MACD turned positive, the stock continued to rise in 27 of 32 cases over the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 34 of 43 cases where MEDX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on MEDX as a result. In 49 of 60 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

Following a +0.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDX advanced for three days, in 176 of 216 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

MEDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for MEDX moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 20 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.

MEDX moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for MEDX crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

The Aroon Indicator for MEDX entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB).

Industry description

The investment seeks to provide long-term growth of capital. The fund is an actively-managed exchange-traded fund (“ETF”) that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries. The fund is non-diversified.

Market Cap

The average market capitalization across the Horizon Kinetics Medical ETF (MEDX) ETF is 136.72B. The market cap for tickers in the group ranges from 2.02M to 1.05T. LLY holds the highest valuation in this group at 1.05T. The lowest valued company is DCOY at 2.02M.

High and low price notable news

The average weekly price growth across all stocks in the Horizon Kinetics Medical ETF (MEDX) ETF was 1%. For the same ETF, the average monthly price growth was -4%, and the average quarterly price growth was 11%. PACB experienced the highest price growth at 18%, while LTRN experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Horizon Kinetics Medical ETF (MEDX) ETF was -62%. For the same stocks of the ETF, the average monthly volume growth was 20% and the average quarterly volume growth was -8%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 38
P/E Growth Rating: 54
Price Growth Rating: 53
SMR Rating: 69
Profit Risk Rating: 70
Seasonality Score: -18 (-100 ... +100)
View a ticker or compare two or three
MEDX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
Listed Funds Trust490 Royal Lake DriveCape Girardeau
Phone
N/A
Web
N/A
MEDX's MACD Histogram just turned positive